Atea Pharmaceuticals Inc expected to post a loss of 50 cents a share - Earnings Preview

Atea Pharmaceuticals

26/02/2024 22:30

* Atea Pharmaceuticals Inc  AVIR.OQ   AVIR.O  is expected
to show
no change in quarterly revenue when it reports  results on
February 28 for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Atea Pharmaceuticals Inc
is
for a loss of 50 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and 2 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Atea
Pharmaceuticals Inc is $3.00​, below​ its last closing price
of $4.20. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.45       -0.48      -0.40     Beat    16.1
 Jun. 30 2023  -0.45       -0.47      -0.34     Beat    27.7
 Mar. 31 2023  -0.47       -0.48      -0.43     Beat    9.9​
 Dec. 31 2022  -0.44       -0.45      -0.41     Beat    8.9
 ​​Sep.        -0.41       -0.44      -0.10     Beat    77.4
 30 2022                                                
 Jun. 30 2022  -0.53       -0.52      -0.38     Beat    27.4​
 Mar. 31 2022  -0.56       -0.58      -0.51     Beat    12.4
 Dec. 31 2021  -0.01       0.17       1.34      Beat    704
 This summary was machine generated February 26 at 22:30 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)